Disclosures for "Clinical, Quality of Life, and Radiological Outcomes Before and After the Implementation of a Standardized Bevacizumab Protocol for Vestibular Schwannomas in NF2-related Schwannomatosis: A Single-center Experience at a Canadian Tertiary Care Institution"
-
Dr. Greciet has nothing to disclose.
-
Dr. Rousseau has nothing to disclose.
-
Ms. Otaner has nothing to disclose.
-
Mrs. Gosselin has nothing to disclose.
-
Mrs. Giasson has nothing to disclose.
-
Dr. Perez Caceres has nothing to disclose.
-
Dr. Saliba has nothing to disclose.
-
Dr. Labidi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Labidi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medexus Pharmaceutical.
-
Prof. el haffaf has nothing to disclose.
-
Dr. Lapointe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.